A potent oral multi-kinase inhibitor getting studied in multiple tumor types currently.

Bayer announces new data about novel anti-cancer compound Bayer today announced outcomes from Phase We and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor getting studied in multiple tumor types currently Käyttäjäkokemuksia . These data were shown at the 45th Annual Interacting with of the American Culture of Clinical Oncology . ‘Bayer is focused on discovering fresh cancer-fighting therapies,’ stated Kemal Malik, MD, Chief Medical Mind and Officer of Global Advancement at Bayer HealthCare.